| The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors S Chen, J Petricca, W Ye, J Guan, Y Zeng, N Cheng, L Gong, SY Shen, ... Nature communications 13 (1), 6467, 2022 | 30 | 2022 |
| Real-world EQ5D health utility scores for patients with metastatic lung cancer by molecular alteration and response to therapy C Labbé, Y Leung, JGS Lemes, E Stewart, C Brown, AP Cosio, M Doherty, ... Clinical Lung Cancer 18 (4), 388-395. e4, 2017 | 26 | 2017 |
| Routine surveillance of chemotherapy toxicities in cancer patients using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) TQ Wang, JN Samuel, MC Brown, A Vennettilli, H Solomon, L Eng, ... Oncology and Therapy 6, 189-201, 2018 | 11 | 2018 |
| Early signatures of breast cancer up to seven years prior to clinical diagnosis in plasma cell-free DNA methylomes N Cheng, K Skead, T Ouellette, S Bratman, D De Carvalho, D Soave, ... | 3 | 2022 |
| Patient-reported health utility scores (HUS) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations by drug therapy EL Stewart, C Labbe, C Brown, A Perez-Cosio, A Vennettilli, D Patel, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 52-52, 2015 | 2 | 2015 |
| Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer N Cheng, K Skead, A Singhawansa, TW Ouellette, M Elliott, DW Cescon, ... medRxiv, 2023.01. 30.23285027, 2023 | 1 | 2023 |
| Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy. C Labbe, EL Stewart, C Brown, A Perez Cosio, A Vennettilli, D Patel, ... Journal of Clinical Oncology 34 (15_suppl), 6567-6567, 2016 | 1 | 2016 |
| Cell-free DNA methylation and fragmentomic signatures identify tissue damage and predict cancer risk N Cheng, K Skead, T Oullette, S Bratman, D De Carvalho, D Soave, ... Cancer Research 84 (6_Supplement), 3454-3454, 2024 | | 2024 |
| Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors EY Stutheit-Zhao, E Sanz-Garcia, Z Liu, D Wong, K Marsh, ... Cancer Discovery, 2024 | | 2024 |
| Immunogenetics of Healthy Aging at the Single Cell Level E Bader, MJ Fave, M Agbessi, J Uzunovic, N Cheng, E Gbeha, V Bruat, ... GENETIC EPIDEMIOLOGY 46 (7), 493-493, 2022 | | 2022 |
| Pre-diagnosis plasma cell-free DNA methylation profiling reveals signatures of cancers up to7 years prior to clinical detection N Cheng, D Soave, K Skead, T Ouellette, S Bratman, D De Carvalho, ... Cancer Research 82 (12_Supplement), 3385-3385, 2022 | | 2022 |
| Leveraging cell-free methylome markers for early cancer detection N Cheng, K Skead, D Soave, J Meng, E Gbeha, I Lungu, B Lam, ... Cancer Research 81 (13_Supplement), 2602-2602, 2021 | | 2021 |
| Pharmacovigilance Data from Systematic Patient Reported Outcome (PRO) Tools Versus Usual Clinician Interactions: Are Cancer Patients Reporting Toxicity Data To Their Health … JN Samuel, TQ Wang, A Perez-Cosio, MC Brown, A Vennettilli, N Cheng, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 448-448, 2015 | | 2015 |
| EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer C Labbe, E Stewart, C Brown, AP Cosio, A Vennettilli, D Patel, N Cheng, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S704-S704, 2015 | | 2015 |
